WO2000065349A3 - Procede de determination d'inhibiteur d'un activateur de plasminogene - Google Patents

Procede de determination d'inhibiteur d'un activateur de plasminogene Download PDF

Info

Publication number
WO2000065349A3
WO2000065349A3 PCT/CA2000/000464 CA0000464W WO0065349A3 WO 2000065349 A3 WO2000065349 A3 WO 2000065349A3 CA 0000464 W CA0000464 W CA 0000464W WO 0065349 A3 WO0065349 A3 WO 0065349A3
Authority
WO
WIPO (PCT)
Prior art keywords
plasminogen activator
activator inhibitor
sample
pai
determining
Prior art date
Application number
PCT/CA2000/000464
Other languages
English (en)
Other versions
WO2000065349A2 (fr
Inventor
Yahia Gawad
Tanya Pekatch
Original Assignee
Cardiogenics Inc
Yahia Gawad
Tanya Pekatch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiogenics Inc, Yahia Gawad, Tanya Pekatch filed Critical Cardiogenics Inc
Priority to AU42799/00A priority Critical patent/AU4279900A/en
Priority to CA002384295A priority patent/CA2384295A1/fr
Publication of WO2000065349A2 publication Critical patent/WO2000065349A2/fr
Publication of WO2000065349A3 publication Critical patent/WO2000065349A3/fr
Priority to US12/138,248 priority patent/US20090004679A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8132—Plasminogen activator inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne un procédé de détermination d'un inhibiteur d'activateur de plasminogène actif de Type (PAI-1) dans un liquide biologique, le procédé comprenant des étapes qui consistent à: (i) disposer d'un liquide biologique; et (ii) mesurer la quantité de complexe PAI-1/vitronectine multimétrique dans l'échantillon pour déterminer le PAI-1 actif dans l'échantillon. L'invention concerne également une trousse pour mettre en oeuvre le procédé.
PCT/CA2000/000464 1999-04-28 2000-04-27 Procede de determination d'inhibiteur d'un activateur de plasminogene WO2000065349A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU42799/00A AU4279900A (en) 1999-04-28 2000-04-27 Method for determining plasminogen activator inhibitor
CA002384295A CA2384295A1 (fr) 1999-04-28 2000-04-27 Procede de determination d'inhibiteur d'un activateur de plasminogene
US12/138,248 US20090004679A1 (en) 1999-04-28 2008-06-12 Method for determining plasminogen activator inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13133999P 1999-04-28 1999-04-28
US60/131,339 1999-04-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/138,248 Continuation US20090004679A1 (en) 1999-04-28 2008-06-12 Method for determining plasminogen activator inhibitor

Publications (2)

Publication Number Publication Date
WO2000065349A2 WO2000065349A2 (fr) 2000-11-02
WO2000065349A3 true WO2000065349A3 (fr) 2001-03-08

Family

ID=22449011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000464 WO2000065349A2 (fr) 1999-04-28 2000-04-27 Procede de determination d'inhibiteur d'un activateur de plasminogene

Country Status (4)

Country Link
US (1) US20090004679A1 (fr)
AU (1) AU4279900A (fr)
CA (1) CA2384295A1 (fr)
WO (1) WO2000065349A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002095411A1 (fr) 2001-05-18 2002-11-28 Virogates Aps Methode de diagnostic ou de pronostic de pathogenes bacteriens respiratoires majeurs chez un sujet
WO2007008966A1 (fr) * 2005-07-12 2007-01-18 The Scripps Research Institute Dosage elisa pour détecter des formes multimériques d'une protéine
CN102812362B (zh) * 2010-01-08 2015-02-11 卡瓦迪斯有限责任公司 用于预测心血管事件的外来体生物标志物的确定
WO2012110099A1 (fr) * 2011-02-18 2012-08-23 Cavadis B.V. Détermination de biomarqueurs exosomaux visant à prévoir des événements cardiovasculaires
WO2012110253A2 (fr) * 2011-02-18 2012-08-23 Cavadis B.V. Biomarqueurs exosomaux pour des événements cardiovasculaires
ES2663482T3 (es) * 2013-08-01 2018-04-12 Fundación Pública Andaluza Progreso Y Salud Método para predecir la respuesta al tratamiento y prueba para el uso seguro de células madre mesenquimatosas en enfermedades inflamatorias
CN108387537A (zh) * 2018-02-01 2018-08-10 中国科学院广州生物医药与健康研究院 一种重金属离子的定量检测方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039028A1 (fr) * 1996-04-12 1997-10-23 American National Red Cross Forme mutante de l'inhibiteur des activateurs du plasminogene du type 1 (iap-1)
WO1998016643A1 (fr) * 1996-10-11 1998-04-23 Human Genome Sciences, Inc. Inhibiteur cerebro-associe de l'activateur du plasminogene de type tissulaire

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8201987A (nl) * 1982-05-13 1983-12-01 Tno Werkwijze voor het bepalen van de activiteit van plasminogeenactivator van het weefseltype, alsmede voor gebruik bij deze werkwijze geschikte combinatie van het "kit"-type.
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US5314994A (en) * 1984-06-22 1994-05-24 Scripps Clinic And Research Foundation Inhibitor of tissue-type and urokinase-type plasminogen activators
US5422245A (en) * 1985-07-12 1995-06-06 Fonden Til Fremme Af Eksperimental Cancerforskning Plasminogen activator inhibitor monoclonal antibodies, hybridomas, monoclonal antibody production and use of the antibodies for assay of the inhibitors
US5102787A (en) * 1987-07-10 1992-04-07 Miho Sasamata Method, device and kit for measurement of tissue plasminogen activator activity
EP0450086A4 (en) * 1989-10-02 1993-03-10 Teijin Limited Kit for immunoassay of human tissue plasminogen activator/human plasminogen activator inhibitor complex and method of immunoassay
FR2661920B1 (fr) * 1990-05-10 1995-10-06 Serbio Procede de determination d'un activateur du plasminogene et de son inhibiteur.
US6514731B1 (en) * 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039028A1 (fr) * 1996-04-12 1997-10-23 American National Red Cross Forme mutante de l'inhibiteur des activateurs du plasminogene du type 1 (iap-1)
WO1998016643A1 (fr) * 1996-10-11 1998-04-23 Human Genome Sciences, Inc. Inhibiteur cerebro-associe de l'activateur du plasminogene de type tissulaire

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DECLERCK ET AL: "Purification and characterization of a plasminogen activator inhibitor binding protein from human plasma", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, no. 30, 25 October 1988 (1988-10-25), pages 15454 - 15461, XP002149851 *
KOST ET AL: "Mapping of binding sites for heparin", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 17, 15 June 1992 (1992-06-15), pages 12098 - 12105, XP002149852 *
LAWRENCE ET AL: "Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 12, 21 March 1997 (1997-03-21), pages 7676 - 7680, XP002149849 *
LAWRENCE ET AL: "Localization of vitronectin binding domain in plasminogen activator inhibitor-1", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 21, 27 May 1994 (1994-05-27), pages 15223 - 15228, XP002149850 *
SEIFFERT D (REPRINT): "The glycosaminoglycan binding site governs ligand binding to the somatomedin B domain of vitronectin", JOURNAL OF BIOLOGICAL CHEMISTRY, (11 APR 1997) VOL. 272, NO. 15, PP. 9971-9978. PUBLISHER: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814. ISSN: 0021-9258., DUPONT MERCK RES LABS, EXPT STN, E400-3438, POB 80400, WILMINGTON, DE 19809 (Reprint);SCRIPPS CLIN & RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037, XP002149848 *

Also Published As

Publication number Publication date
AU4279900A (en) 2000-11-10
CA2384295A1 (fr) 2000-11-02
US20090004679A1 (en) 2009-01-01
WO2000065349A2 (fr) 2000-11-02

Similar Documents

Publication Publication Date Title
AU2001288032A1 (en) Method and kit for the transderaml determination of analyte concentration in blood
WO2002066671A3 (fr) Procede perfectionne de detection de l'atp
AU2002249837A1 (en) Homo-doubly labeled compositions for the detection of enzyme activity in biological samples
CA2366682A1 (fr) Inhibiteur tissulaire de metalloproteinases matricielles type-1 (timp-1) comme marqueur de cancer
HU0002275D0 (en) Electrochemical method and arrangement for determining of switching time of a biological fluid
AU5959800A (en) Method of measuring concentration of luminescent materials in turbid media
NO964982D0 (no) Detektering av reticulocytter
CA2310616A1 (fr) Procede et dispositif de conservation de la salive humaine a analyser
AU3491599A (en) Sensor probe for determining hydrogen peroxide concentration and method of use thereof
HK1055949A1 (en) Benzophenones as inhibitors of il-1b and tnf-a
AU2002330261A1 (en) Measurement of concentration of material in a process fluid
EP1396724A4 (fr) Procede d'analyse par immunoreaction, et reactif correspondant
AU3416200A (en) Method for determining the concentration of thrombin inhibitors
AU1461902A (en) Method of determining global coagulability and hemostatic potential
AU6187296A (en) Process and device for determining the activity of enzymes in liquids, or the concentration and/or activity of inhibitors in liquids
WO2000065349A3 (fr) Procede de determination d'inhibiteur d'un activateur de plasminogene
NZ334518A (en) Homocysteine desulphurase from the protozoan trichomonas vaginalis
AU2003250741A1 (en) Ultrasonic measurement of the running time and quantity for detecting the concentration of particles in a flowing fluid
EP0297597A3 (en) Method for determining the activity of serine proteinases or serine proteinase inhibitors
WO2000068414A3 (fr) Dosage de cellules entières pour la cathepsine k
WO2004039244A3 (fr) Procedes et trousses pour diagnostiquer une cancerogenicite
CA2339821A1 (fr) Mesure enzymatique de l'acide mycophenolique
DE3568189D1 (en) Method for the determination of fibrin monomer in plasma
AU2001286915A1 (en) Method for simplified shipping of clinical specimens and optional direct analysis
AUPR576901A0 (en) Improved method of measuring changes in microvascular capillary blood flow

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2384295

Country of ref document: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10049727

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP